TICKERNOMICS Sign up
Last Update: 2023-10-04 11:38:08
Sierra Oncology Inc ( SRRA ) https://www.sierraoncology.com
54.99USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
SRRA
0.00%
SPY
36.71%
SRRA
418.77%
SPY
70.96%
-18.17%
SRRA
SPY
262.36%
SRRA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1152.91
884.83
0.86
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-11.23
1847.61
4.41
-15.20
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-22486.29
100.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
1.2145
-61.12
-61.38
-1.05
Other Earnings and Cash Flow Stats:
Sierra Oncology Inc ( SRRA ) Net Income TTM ($MM) is -97.12
Sierra Oncology Inc ( SRRA ) Operating Income TTM ($MM) is -96.88
Sierra Oncology Inc ( SRRA ) Owners' Earnings Annual ($MM) is -87.89
Sierra Oncology Inc ( SRRA ) Current Price to Owners' Earnings ratio is -7.72
Sierra Oncology Inc ( SRRA ) EBITDA TTM ($MM) is -96.57
Sierra Oncology Inc ( SRRA ) EBITDA Margin is 0.00%
Capital Allocation:
Sierra Oncology Inc ( SRRA ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Sierra Oncology Inc ( SRRA ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Sierra Oncology Inc ( SRRA ) Interest-bearing Debt ($MM) as of last quarter is 5
Sierra Oncology Inc ( SRRA ) Annual Working Capital Investments ($MM) are 0
Sierra Oncology Inc ( SRRA ) Book Value ($MM) as of last quarter is 261
Sierra Oncology Inc ( SRRA ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Sierra Oncology Inc ( SRRA ) has 274 million in cash on hand as of last quarter
Sierra Oncology Inc ( SRRA ) has 13 million of liabilities due within 12 months, and long term debt 6 as of last quarter
Sierra Oncology Inc ( SRRA ) has 20 common shares outstanding as of last quarter
Sierra Oncology Inc ( SRRA ) has 0 million USD of preferred stock value
Academic Scores:
Sierra Oncology Inc ( SRRA ) Altman Z-Score is 0.00 as of last quarter
Sierra Oncology Inc ( SRRA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Sierra Oncology Inc ( SRRA ) largest shareholder is Two Sigma Advisers, LLC owning 256556 shares at 14.11 ($MM) value
William D Turner(an insider) Sold 100 shares of Sierra Oncology Inc ( SRRA ) for the amount of $3709.00 on 2022-04-05
8.50% of Sierra Oncology Inc ( SRRA ) is held by insiders, and 76.95% is held by institutions
Sierra Oncology Inc ( SRRA ) went public on 2015-07-16
Other Sierra Oncology Inc ( SRRA ) financial metrics:
FCF:-89.60
Unlevered Free Cash Flow:-99.20
EPS:-8.43
Operating Margin:-22486.29
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-42.70
Beta:-1.05
Buffet's Owners Earnings:-87.89
Price to Owner's Earnings:-7.72
About Sierra Oncology Inc ( SRRA ) :
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.